In conclusion, this systematic review and meta‐analysis demonstrates that GLP‐1 or dual GIP/GLP‐1 RAs are associated with a significantly lower risk of papilledema and visual disturbances or blindness compared with the standard of care, while GLP‐1 RAs also significantly reduce the monthly headache burden in IIH. This evidence concerns the gene GIP and optic papillitis.